An existing drug has shown it can significantly improve the quality of sleep for those suffering from obstructive sleep apnea (OSA), so much so that many trial participants were able to hang up their CPAP machines. It could be the first therapeutic to effectively treat the condition that affects an estimated 936 million people worldwide.